

**Subject** MA reimbursement for biological products to treat rare diseases

**Authors** Bierman and others

**Analyst** Annie Mach

**Date** March 20, 2026

## Summary

H.F. 4349 modifies how the Medical Assistance (MA) program reimburses hospitals for biological products provided in an inpatient hospital setting as part of cell or gene therapy to treat rare diseases. Under the bill, MA must provide separate reimbursement to hospitals for the products, and the reimbursement amount must be the actual acquisition cost for the products.